Allergy Therapeutics (LON:AGY) Stock Price Down 10.4% – Should You Sell?

Allergy Therapeutics plc (LON:AGY)’s stock price traded down 10.4% during trading on Monday . The stock traded as low as GBX 5.62 ($0.07) and last traded at GBX 6.28 ($0.08). 180,738 shares changed hands during trading, a decline of 66% from the average session volume of 535,030 shares. The stock had previously closed at GBX 7 ($0.09).

Allergy Therapeutics Stock Down 17.1 %

The company has a debt-to-equity ratio of 37.22, a quick ratio of 1.48 and a current ratio of 1.40. The stock’s fifty day simple moving average is GBX 6.53 and its two-hundred day simple moving average is GBX 5.42. The stock has a market capitalization of £276.66 million, a P/E ratio of -96.67, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40.

Allergy Therapeutics (LON:AGY) last issued its quarterly earnings results on Wednesday, November 6th. The company reported GBX (1.07) (($0.01)) earnings per share for the quarter. Allergy Therapeutics had a negative net margin of 94.29% and a negative return on equity of 155.90%. As a group, research analysts expect that Allergy Therapeutics plc will post -2.56 EPS for the current fiscal year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.